Completely Responsive Multiple Liver Recurrence of Colon Cancer Treated Using Chemotherapy with Oral S-1 and Oxaliplatin Plus Bevacizumab : A Case Report.

Akira Kabashima, Koichi Kimura, Kensakuet Sanefuji, Soichiro Maekawa
{"title":"Completely Responsive Multiple Liver Recurrence of Colon Cancer Treated Using Chemotherapy with Oral S-1 and Oxaliplatin Plus Bevacizumab : A Case Report.","authors":"Akira Kabashima,&nbsp;Koichi Kimura,&nbsp;Kensakuet Sanefuji,&nbsp;Soichiro Maekawa","doi":"","DOIUrl":null,"url":null,"abstract":"<p><p>Although chemotherapy with oral S-1and oxaliplatin (SOX) plus bevacizumab (bev) is safe and\nfeasible for patients with advanced or recurrent colorectal cancer, it is difficult to achieve a complete\nresponse (CR) using only chemotherapy. A 67-year-old man underwent endoscopic mucosal resection\nand additional sigmoidectomy (D2 dissection) for submucosal invasive sigmoid colon cancer. Multiple\nliver metastases were diagnosed 1.5 years later, and chemotherapy with SOX + bev was initiated.\nComputed tomography (CT) after the end of the third course revealed reduced liver recurrence. Liver\nmetastases could not be identified using CT after the end of the sixth course. Grade 1peripheral\nneuropathy was the only side effect of this regimen. Subsequently, the chemotherapy regimen was\nchanged to oral S-1. CT evaluation revealed that there was no recurrence at 6 months after the\nregimen change.</p>","PeriodicalId":12665,"journal":{"name":"Fukuoka igaku zasshi = Hukuoka acta medica","volume":"108 1","pages":"8-13"},"PeriodicalIF":0.0000,"publicationDate":"2017-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Fukuoka igaku zasshi = Hukuoka acta medica","FirstCategoryId":"1085","ListUrlMain":"","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Although chemotherapy with oral S-1and oxaliplatin (SOX) plus bevacizumab (bev) is safe and feasible for patients with advanced or recurrent colorectal cancer, it is difficult to achieve a complete response (CR) using only chemotherapy. A 67-year-old man underwent endoscopic mucosal resection and additional sigmoidectomy (D2 dissection) for submucosal invasive sigmoid colon cancer. Multiple liver metastases were diagnosed 1.5 years later, and chemotherapy with SOX + bev was initiated. Computed tomography (CT) after the end of the third course revealed reduced liver recurrence. Liver metastases could not be identified using CT after the end of the sixth course. Grade 1peripheral neuropathy was the only side effect of this regimen. Subsequently, the chemotherapy regimen was changed to oral S-1. CT evaluation revealed that there was no recurrence at 6 months after the regimen change.

口服S-1和奥沙利铂加贝伐单抗化疗治疗多发性肝脏复发结肠癌的完全应答:1例报告
虽然口服s -1和奥沙利铂(SOX)加贝伐单抗(bevizumab)化疗对于晚期或复发性结直肠癌患者是安全可行的,但仅使用化疗很难达到完全缓解(CR)。一位67岁的男性接受内镜粘膜切除术和附加乙状结肠切除术(D2夹层)治疗粘膜下浸润性乙状结肠癌。1年半后被诊断为多发性转移,并开始用SOX + bev化疗。第三疗程结束后的计算机断层扫描(CT)显示肝脏复发减少。在第6个疗程结束后,CT无法发现肝转移。1级周围神经病变是该方案唯一的副作用。随后化疗方案改为口服S-1。CT检查显示改变方案后6个月无复发。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信